Fibrosing connective tissue disorders of the skin: Molecular similarities and distinctions

Journal of Dermatological Science

Volumn 70, Issue 3, 2013, Pages 151-158

  Canady, Johanna ^a   Karrer, Sigrid ^a   Fleck, Martin ^a   Bosserhoff, Anja K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Connective tissue; Fibrosis; MiRNA; Signaling

Indexed keywords

ACTIVIN A; CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE A; GELATINASE B; GLYCOPROTEIN GP 130; INTERLEUKIN 2; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; STAT3 PROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONNECTIVE TISSUE DISEASE; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; EOSINOPHILIC FASCIITIS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HYDROLYSIS; HYPERTROPHIC SCAR; IMMUNOREACTIVITY; KELOID; LICHEN SCLEROSUS ET ATROPHICUS; MOLECULAR DYNAMICS; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SCLERODERMA; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN FIBROSIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; WOUND HEALING;

CONNECTIVE TISSUE DISEASES; EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; SIGNAL TRANSDUCTION; SKIN; SKIN DISEASES;

EID: 84878127178     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.03.005     Document Type: Review

References (88)

1. Zhu H., Li Y., Qu S., Luo H., Zhou Y., Wang Y., et al. MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol 2012, 32(3):514-522.
2. Medsger T.A. Epidemiology of systemic sclerosis. Clin Dermatol 1994, 12:207-216.
3. Gilliam A.C. Scleroderma. Curr Dir Autoimmun 2008, 10:258-279.
4. Tan F.K., Wang N., Kuwana M., Chakraborty R., Bona C.A., Milewicz D.M., et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001, 44:893-901.
5. Genth E., Krieg T. Systemic sclerosis - diagnosis and classification. Z Rheumatol 2006, 65:268-274.
6. Fleming J.N., Shulman H.M., Nash R.A., Johnson P.Y., Wight T.N., Gown A., et al. Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS ONE 2009, 4:e6203.
7. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 2010, 37:11-25.
8. Sato S., Hayakawa I., Hasegawa M., Fujimoto M., Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003, 120:542-547.
9. Nishijima C., Hayakawa I., Matsushita T., Komura K., Hasegawa M., Takehara K., et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004, 138:357-363.
10. Young-Min S.A., Beeton C., Laughton R., Plumpton T., Bartram S., Murphy G., et al. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis 2001, 60:846-851.
11. Nietert P.J., Mitchell H.C., Bolster M.B., Shaftman S.R., Tilley B.C., Silver R.M. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol 2006, 33:263-268.
12. Korn J.H. Scleroderma: a treatable disease. Cleve Clin J Med 2003, 70:954-956. 958 passim.
13. Bhattacharyya S., Wei J., Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011, 8:42-54.
14. O'Reilly S., Hügle T., Van Laar J.M. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford) 2012, 51:1540-1549.
15. Jun J.-B., Kuechle M., Min J., Shim S.C., Kim G., Montenegro V., et al. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J Invest Dermatol 2005, 124:298-303.
16. Khan K., Xu S., Nihtyanova S., Derrett-Smith E., Abraham D., Denton C.P., et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012, 71:1235-1242.
17. O'Donoghue R.J.J., Knight D.A., Richards C.D., Prêle C.M., Lau H.L., Jarnicki A.G., et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med 2012, 4(9):939-951.
18. Avouac J., Fürnrohr B.G., Tomcik M., Palumbo K., Zerr P., Horn A., et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011, 63:800-809.
19. Karrer S., Bosserhoff A.K., Weiderer P., Distler O., Landthaler M., Szeimies R.-M., et al. The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005, 124:92-98.
20. Romano E., Manetti M., Guiducci S., Ceccarelli C., Allanore Y., Matucci-Cerinic M. The genetics of systemic sclerosis: an update. Clin Exp Rheumatol 2011, 29:S75-S86.
21. Arnett F.C., Gourh P., Shete S., Ahn C.W., Honey R.E., Agarwal S.K., et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010, 69:822-827.
22. Maurer B., Stanczyk J., Jüngel A., Akhmetshina A., Trenkmann M., Brock M., et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010, 62:1733-1743.
23. Honda N., Jinnin M., Kajihara I., Makino T., Makino K., Masuguchi S., et al. TGF-β-mediated downregulation of MicroRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J Immunol 2012, 188:3323-3331.
24. Clark S. Animal models in scleroderma. Curr Rheumatol Rep 2005, 7:150-155.
25. Smith G.P., Chan E.S.L. Molecular pathogenesis of skin fibrosis: insight from animal models. Curr Rheumatol Rep 2010, 12:26-33.
26. Fett N., Werth V.P. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011, 64:217-228. [quiz 229-30].
27. Takehara K., Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford) 2005, 44:274-279.
28. Leitenberger J.J., Cayce R.L., Haley R.W., Adams-Huet B., Bergstresser P.R., Jacobe H.T. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 2009, 145:545-550.
29. Torres J.E., Sánchez J.L. Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol 1998, 20:242-245.
30. Kurzinski K., Torok K.S. Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine 2011, 55:157-164.
31. Passos C.O., Werneck C.C., Onofre G.R., Pagani E.A., Filgueira A.L., Silva L.-C. Comparative biochemistry of human skin: glycosaminoglycans from different body sites in normal subjects and in patients with localized scleroderma. J Eur Acad Dermatol Venereol 2003, 17:14-19.
32. Tomimura S., Ogawa F., Iwata Y., Komura K., Hara T., Muroi E., et al. Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma. J Dermatol Sci 2008, 52:47-54.
33. Satish L., Lyons-Weiler J., Hebda P.A., Wells A. Gene expression patterns in isolated keloid fibroblasts. Wound Repair Regen 2006, 14:463-470.
34. Verhaegen P.D.H.M., Van Zuijlen P.P.M., Pennings N.M., Van Marle J., Niessen F.B., Van Der Horst C.M.A.M., et al. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: an objective histopathological analysis. Wound Repair Regen 2009, 17:649-656.
35. Meyer L.J., Russell S.B., Russell J.D., Trupin J.S., Egbert B.M., Shuster S., et al. Reduced hyaluronan in keloid tissue and cultured keloid fibroblasts. J Invest Dermatol 2000, 114:953-959.
36. Chipev C.C., Simman R., Hatch G., Katz A.E., Siegel D.M., Simon M. Myofibroblast phenotype and apoptosis in keloid and palmar fibroblasts in vitro. Cell Death Differ 2000, 7:166-176.
37. Ulrich D., Ulrich F., Unglaub F., Piatkowski A., Pallua N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids. J Plast Reconstr Aesthet Surg 2010, 63:1015-1021.
38. Brown J.J., Ollier W.E.R., Thomson W., Bayat A. Positive association of HLA-DRB1*15 with keloid disease in Caucasians. Int J Immunogenet 2008, 35:303-307.
39. Seifert O., Mrowietz U. Keloid scarring: bench and bedside. Arch Dermatol Res 2009, 301(4):259-272.
40. Lim C.P., Phan T.-T., Lim I.J., Cao X. Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration. Oncogene 2006, 25:5416-5425.
41. Ghazizadeh M., Tosa M., Shimizu H., Hyakusoku H., Kawanami O. Functional implications of the IL-6 signaling pathway in keloid pathogenesis. J Invest Dermatol 2007, 127:98-105.
42. Brown J.J., Ollier W., Arscott G., Ke X., Lamb J., Day P., et al. Genetic susceptibility to keloid scarring: SMAD gene SNP frequencies in Afro-Caribbeans. Exp Dermatol 2008, 17:610-613.
43. Nakashima M., Chung S., Takahashi A., Kamatani N., Kawaguchi T., Tsunoda T., et al. A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population. Nat Genet 2010, 42:768-771.
44. Kashiyama K., Mitsutake N., Matsuse M., Ogi T., Saenko V.A., Ujifuku K., et al. miR-196a downregulation increases the expression of Type I and III collagens in keloid fibroblasts. J Invest Dermatol 2012, 132(6):1597-1604.
45. Liu Y., Yang D., Xiao Z., Zhang M. miRNA expression profiles in keloid tissue and corresponding normal skin tissue. Aesthetic Plast Surg 2012, 36:193-201.
46. Wang H., Luo S. Establishment of an animal model for human keloid scars using tissue engineering method. J Burn Care Res 2012, [Epub ahead of print].
47. Mahdavian Delavary B., Van der Veer W.M., Ferreira J.A., Niessen F.B. Formation of hypertrophic scars: evolution and susceptibility. J Plast Surg Hand Surg 2012, 46:95-101.
48. Gabriel V. Hypertrophic scar. Phys Med Rehabil Clin N Am 2011, 22(vi):301-310.
49. Bock O., Yu H., Zitron S., Bayat A., Ferguson M.W.J., Mrowietz U. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars. Acta Derm Venereol 2005, 85:216-220.
50. Cheng B., Fu X., Sun T., Sun X., Sheng Z. Expression of epidermal growth factor receptor and related phosphorylation proteins in hypertrophic scars and normal skin. Chin Med J 2002, 115:1525-1528.
51. Laurentaci G., Dioguardi D. HLA antigens in keloids and hypertrophic scars. Arch Dermatol 1977, 113:1726.
52. McCarty S.M., Syed F., Bayat A. Influence of the human leukocyte antigen complex on the development of cutaneous fibrosis: an immunogenetic perspective. Acta Derm Venereol 2010, 90:563-574.
53. Ramos M.L.C., Gragnani A., Ferreira L.M. Is there an ideal animal model to study hypertrophic scarring?. J Burn Care Res 2008, 29:363-368.
54. Momtazi M., Kwan P., Ding J., Anderson C.C., Honardoust D., Goekjian S., et al. A nude mouse model of hypertrophic scar shows morphologic and histologic characteristics of human hypertrophic scar. Wound Repair Regen 2013, 21:77-87.
55. Bischoff L., Derk C.T. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol 2008, 47:29-35.
56. Kähäri V.M., Heino J., Niskanen L., Fräki J., Uitto J. Eosinophilic fasciitis. Increased collagen production and type I procollagen messenger RNA levels in fibroblasts cultured from involved skin. Arch Dermatol 1990, 126:613-617.
57. Jinnin M., Ihn H., Yamane K., Asano Y., Yazawa N., Tamaki K. Serum levels of tissue inhibitor of metalloproteinase-1 and 2 in patients with eosinophilic fasciitis. Br J Dermatol 2004, 151:407-412.
58. Lakhanpal S., Ginsburg W.W., Michet C.J., Doyle J.A., Moore S.B. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 1988, 17:221-231.
59. Dziadzio L., Kelly E.A., Panzer S.E., Jarjour N., Huttenlocher A. Cytokine abnormalities in a patient with eosinophilic fasciitis. Ann Allergy Asthma Immunol 2003, 90:452-455.
60. Anderson S.T., Klein E.C. Eosinophilic fasciitis in a rhesus macaque. Arthritis Rheum 1992, 35:714-716.
61. Powell J.J., Wojnarowska F. Lichen sclerosus. Lancet 1999, 353:1777-1783.
62. Neill S.M., Lewis F.M., Tatnall F.M., Cox N.H. British Association of Dermatologists' guidelines for the management of lichen sclerosus 2010. Br J Dermatol 2010, 163:672-682.
63. Aynaud O., Piron D., Casanova J.M. Incidence of preputial lichen sclerosus in adults: histologic study of circumcision specimens. J Am Acad Dermatol 1999, 41:923-926.
64. Walkden, Yoon Chia Fenella Wojnarow V. The association of squamous cell carcinoma of the vulva and lichen sclerosus: implications for management and follow up. J Obstet Gynaecol 1997, 17:551-553.
65. Val I., Almeida G. An overview of lichen sclerosus. Clin Obstet Gynecol 2005, 48:808-817.
66. De Oliveira G.A.P., De Almeida M.P., Soares F.A., De Almeida Filho G.L., Takiya C.M., Otazu I.B., et al. Metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 are increased in vulvar lichen sclerosus. Eur J Obstet Gynecol Reprod Biol 2012, 161:96-101.
67. Powell J., Wojnarowska F., Winsey S., Marren P., Welsh K. Lichen sclerosus premenarche: autoimmunity and immunogenetics. Br J Dermatol 2000, 142:481-484.
68. Birenbaum D.L., Young R.C. High prevalence of thyroid disease in patients with lichen sclerosus. J Reprod Med 2007, 52:28-30.
69. Oyama N., Chan I., Neill S., Hamada T., South A., Wessagowit V., et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet 2003, 362:118-123.
70. Edmonds E.V.J., Oyama N., Chan I., Francis N., McGrath J.A., Bunker C.B. Extracellular matrix protein 1 autoantibodies in male genital lichen sclerosus. Br J Dermatol 2011, 165:218-219.
71. Pugliese J.M., Morey A.F., Peterson A.C. Lichen sclerosus: review of the literature and current recommendations for management. J Urol 2007, 178:2268-2276.
72. Gao X.-H., Barnardo M.C.M.N., Winsey S., Ahmad T., Cook J., Agudelo J.D., et al. The association between HLA DR, DQ antigens, and vulval lichen sclerosus in the UK: HLA DRB112 and its associated DRB112/DQB10301/04/09/010 haplotype confers susceptibility to vulval lichen sclerosus, and HLA DRB10301/04 and its associated DRB10301/04/DQB10201/02/03 haplotype protects from vulval lichen sclerosus. J Invest Dermatol 2005, 125:895-899.
73. Clay F.E., Tarlow J.K., Cork M.J., Cox A., Nicklin M.J., Duff G.W. Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. Hum Genet 1996, 97:723-726.
74. Farrell A.M., Dean D., Millard P.R., Charnock F.M., Wojnarowska F. Cytokine alterations in lichen sclerosus: an immunohistochemical study. Br J Dermatol 2006, 155:931-940.
75. Terlou A., Santegoets L.A.M., Van der Meijden W.I., Heijmans-Antonissen C., Swagemakers S.M.A., Van der Spek P.J., et al. An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: a Th1 response and high levels of microRNA-155. J Invest Dermatol 2012, 132:658-666.
76. Martires K.J., Baird K., Steinberg S.M., Grkovic L., Joe G.O., Williams K.M., et al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood 2011, 118:4250-4257.
77. Fimiani M., De Aloe G., Cuccia A. Chronic graft versus host disease and skin. J Eur Acad Dermatol Venereol 2003, 17:512-517.
78. Koreth J., Matsuoka K., Kim H.T., McDonough S.M., Bindra B., Alyea E.P., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011, 365:2055-2066.
79. Chiang K.-Y., Abhyankar S., Bridges K., Godder K., Henslee-Downey J.P. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002, 73:665-667.
80. Ma H.-H., Ziegler J., Li C., Sepulveda A., Bedeir A., Grandis J., et al. Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3. Cell Immunol 2011, 268:37-46.
81. Salmela M.T., Karjalainen-Lindsberg M.L., Jeskanen L., Saarialho-Kere U. Overexpression of tissue inhibitor of metalloproteinases-3 in intestinal and cutaneous lesions of graft-versus-host disease. Mod Pathol 2003, 16:108-114.
82. Espinoza J.L., Takami A., Nakata K., Onizuka M., Kawase T., Akiyama H., et al. A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS ONE 2011, 6:e26229.
83. Broen K., Van der Waart A.B., Greupink-Draaisma A., Metzig J., Feuth T., Schaap N.P.M., et al. Polymorphisms in CCR6 are associated with chronic graft-versus-host disease and invasive fungal disease in matched-related hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1443-1449.
84. Arora M., Lindgren B., Basu S., Nagaraj S., Gross M., Weisdorf D., et al. Polymorphisms in the base excision repair pathway and graft-versus-host disease. Leukemia 2010, 24:1470-1475.
85. Ranganathan P., Heaphy C.E.A., Costinean S., Stauffer N., Na C., Hamadani M., et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood 2012, 119(20):4786-4797.
86. Schroeder M.A., DiPersio J.F. Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech 2011, 4:318-333.
87. Varga J., Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009, 5:200-206.
88. Ma L., Zhuang S. The Role of STAT 3 in Tissue Fibrosis. Curr Chem Biol 2011, 5:44-51.